Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-01-2019 | Review – Cancer Research

Microbiota in cancer development and treatment

Authors: Muhammad Hassan Raza, Kamni Gul, Abida Arshad, Naveeda Riaz, Usman Waheed, Abdul Rauf, Fahad Aldakheel, Shatha Alduraywish, Maqbool Ur Rehman, Muhammad Abdullah, Muhammad Arshad

Published in: Journal of Cancer Research and Clinical Oncology | Issue 1/2019

Abstract

Purpose

Human microbiota comprises of a variety of organisms ranging from bacterial species to viruses, fungi, and protozoa which are present on the epidermal and mucosal barriers of the body. It plays a key role in health and survival of the host by regulation of the systemic functions. Its apparent functions in modulation of the host immune system, inducing carcinogenesis and regulation of the response to the cancer therapy through a variety of mechanisms such as bacterial dysbiosis, production of genotoxins, pathobionts, and disruption of the host metabolism are increasingly becoming evident.

Methods

Different electronic databases such as PubMed, Google Scholar, and Web of Science were searched for relevant literature which has been reviewed in this article.

Results

Characterization of the microbiome particularly gut microbiota, understanding of the host–microbiota interactions, and its potential for therapeutic exploitation are necessary for the development of novel anticancer therapeutic strategies with better efficacy and lowered off-target side effects.

Conclusion

In this review, the role of microbiota is explained in carcinogenesis, mechanisms of microbiota-mediated carcinogenesis, and role of gut microbiota in modulation of cancer therapy.

Abdulamir AS, Hafidh RR, Bakar FA (2010) Molecular detection, quantification, and isolation of Streptococcus gallolyticus bacteria colonizing colorectal tumors: inflammation-driven potential of carcinogenesis via IL-1, COX-2, and IL-8. Mol Cancer 9:249CrossRefPubMedPubMedCentral

Alam B, Saporoschetz I, Epstein S (1971) Synthesis of nitrosopiperidine from nitrate and piperidine in the gastro-intestinal tract of the rat. Nature 232:199CrossRefPubMed

Allen-Vercoe E, Strauss J, Chadee K (2011) Fusobacterium nucleatum: an emerging gut pathogen? Gut Microbes 2:294–298CrossRefPubMed

Al-Mayah A et al (2015) The non-targeted effects of radiation are perpetuated by exosomes. Mutat Res Fundam Mol Mech Mutagen 772:38–45CrossRef

Apostolou P, Tsantsaridou A, Papasotiriou I, Toloudi M, Chatziioannou M, Giamouzis G (2011) Bacterial and fungal microflora in surgically removed lung cancer samples. J Cardiothorac Surg 6:137CrossRefPubMedPubMedCentral

Arthur JC et al (2012) Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 338:120–123CrossRefPubMedPubMedCentral

Attene-Ramos MS, Wagner ED, Plewa MJ, Gaskins HR (2006) Evidence that hydrogen sulfide is a genotoxic agent. Mol Cancer Res 4:9–14CrossRefPubMed

Baek MK et al (2010) Lithocholic acid upregulates uPAR and cell invasiveness via MAPK and AP-1 signaling in colon cancer cells. Cancer Lett 290:123–128CrossRefPubMed

Barker HE, Paget JT, Khan AA, Harrington KJ (2015) The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer 15:409CrossRefPubMedPubMedCentral

Bayerdörffer E et al (1995) Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. Lancet 345:1591–1594CrossRefPubMed

Belcheva A et al (2014) Gut microbial metabolism drives transformation of MSH2-deficient colon epithelial cells. Cell 158:288–299CrossRefPubMed

Belkaid Y, Hand TW (2014) Role of the microbiota in immunity and inflammation. Cell 157:121–141CrossRefPubMedPubMedCentral

Belkaid Y, Naik S (2013) Compartmentalized and systemic control of tissue immunity by commensals. Nat Immunol 14:646–653CrossRefPubMed

Bernstein C, Holubec H, Bhattacharyya AK, Nguyen H, Payne CM, Zaitlin B, Bernstein H (2011) Carcinogenicity of deoxycholate, a secondary bile acid. Arch Toxicol 85:863–871CrossRefPubMedPubMedCentral

Bindels LB et al (2012) Gut microbiota-derived propionate reduces cancer cell proliferation in the liver. Br J Cancer 107:1337CrossRefPubMedPubMedCentral

Boleij A et al (2014) The Bacteroides fragilis toxin gene is prevalent in the colon mucosa of colorectal cancer patients. Clin Infect Dis 60:208–215CrossRefPubMedPubMedCentral

Bonnet M et al (2014) Colonization of the human gut by E. coli and colorectal cancer risk. Clin Cancer Res 20:859–867CrossRefPubMed

Boulangé CL, Neves AL, Chilloux J, Nicholson JK, Dumas M-E (2016) Impact of the gut microbiota on inflammation, obesity, and metabolic disease. Genome Med 8:42CrossRefPubMedPubMedCentral

Broin P et al (2015) Intestinal microbiota-derived metabolomic blood plasma markers for prior radiation injury. Int J Radiat Oncol Biol Phys 91:360–367CrossRefPubMedCentral

Carbone C et al (2018) Angiopoietin-like proteins in angiogenesis inflammation and cancer. Int J Mol Sci 19:431CrossRefPubMedCentral

Carbonero F, Benefiel AC, Alizadeh-Ghamsari AH, Gaskins HR (2012) Microbial pathways in colonic sulfur metabolism and links with health and disease. Front Physiol 3:448CrossRefPubMedPubMedCentral

Castellarin M et al (2012) Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res 22:299–306CrossRefPubMedPubMedCentral

Caygill CP, Hill MJ, Braddick M, Sharp JC (1994) Cancer mortality in chronic typhoid and paratyphoid carriers. Lancet 343:83–84CrossRefPubMed

Chan PJ, Seraj IM, Kalugdan TH, King A (1996) Prevalence of mycoplasma conserved DNA in malignant ovarian cancer detected using sensitive PCR-ELISA. Gynecol Oncol 63:258–260CrossRefPubMed

Chang MC, Keasling JD (2006) Production of isoprenoid pharmaceuticals by engineered microbes. Nat Chem Biol 2:674–681CrossRefPubMed

Chanudet E et al (2007) Chlamydiae and Mycoplasma infections in pulmonary MALT lymphoma. Br J Cancer 97:949CrossRefPubMedPubMedCentral

Chaput N et al (2017) Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol 28:1368–1379CrossRefPubMed

Chen GY, Shaw MH, Redondo G, Núñez G (2008) The innate immune receptor Nod1 protects the intestine from inflammation-induced tumorigenesis. Cancer Res 68:10060–10067CrossRefPubMedPubMedCentral

Chen W, Liu F, Ling Z, Tong X, Xiang C (2012) Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer. PLoS One 7:e39743CrossRefPubMedPubMedCentral

Cho JH (2008) The genetics and immunopathogenesis of inflammatory bowel disease. Nat Rev Immunol 8:458CrossRefPubMed

Clarke G, Stilling RM, Kennedy PJ, Stanton C, Cryan JF, Dinan TG (2014) Minireview: Gut microbiota: the neglected endocrine organ. Mol Endocrinol 28:1221–1238CrossRefPubMedPubMedCentral

Cong J, Zhang X (2018) How human microbiome talks to health and disease. Eur J Clin Microbiol Infect Dis 37:1595–1601CrossRefPubMed

Consortium HMP (2012) Structure, function and diversity of the healthy human microbiome. Nature 486:207–214CrossRef

Cotillard A et al (2013) Dietary intervention impact on gut microbial gene richness. Nature 500:585CrossRefPubMed

Couturier-Maillard A et al (2013) NOD2-mediated dysbiosis predisposes mice to transmissible colitis and colorectal cancer. J Clin Investig 123(2):700–711PubMedPubMedCentral

Cuevas-Ramos G, Petit CR, Marcq I, Boury M, Oswald E, Nougayrède J-P (2010) Escherichia coli induces DNA damage in vivo and triggers genomic instability in mammalian cells. Proc Natl Acad Sci 107:11537–11542CrossRefPubMedPubMedCentral

Dapito DH et al (2012) Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 21:504–516CrossRefPubMedPubMedCentral

De Martel C, Plummer M, Parsonnet J, Van Doorn L, Franceschi S (2009) Helicobacter species in cancers of the gallbladder and extrahepatic biliary tract. Br J Cancer 100:194CrossRefPubMed

Devkota S et al (2012) Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10–/– mice. Nature 487:104CrossRefPubMedPubMedCentral

DeWeerdt S (2011) Food: the omnivore’s labyrinth. Nature 471:S22–S24CrossRefPubMed

Dong L, Li J, Liu Y, Yue W, Luo X (2012) Toll‐like receptor 2 monoclonal antibody or/and Toll‐like receptor 4 monoclonal antibody increase counts of Lactobacilli and Bifidobacteria in dextran sulfate sodium‐induced colitis in mice. J Gastroenterol Hepatol 27:110–119CrossRefPubMed

Donohoe DR, Garge N, Zhang X, Sun W, O’Connell TM, Bunger MK, Bultman SJ (2011) The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon. Cell Metab 13:517–526CrossRefPubMedPubMedCentral

Dutton RJ, Turnbaugh PJ (2012) Taking a metagenomic view of human nutrition. Curr Opin Clin Nutr Metab Care 15:448–454CrossRefPubMed

Dzutsev A, Goldszmid RS, Viaud S, Zitvogel L, Trinchieri G (2015) The role of the microbiota in inflammation, carcinogenesis, and cancer therapy. Eur J Immunol 45:17–31CrossRefPubMed

Elinav E, Strowig T, Henao-Mejia J, Flavell RA (2011) Regulation of the antimicrobial response by NLR proteins. Immunity 34:665–679CrossRefPubMed

Epplein M, Pawlita M, Michel A, Peek RM, Cai Q, Blot WJ (2013) Helicobacter pylori protein—specific antibodies and risk of colorectal cancer. Cancer Epidemiol Prev Biomark 22(11):1964–1974CrossRef

Faith JJ et al (2013) The long-term stability of the human gut microbiota. Science 341:1237439CrossRefPubMedPubMedCentral

Feng R et al (2015) Transforming berberine into its intestine-absorbable form by the gut microbiota. Sci Rep 5:12155CrossRefPubMedPubMedCentral

Ferreri AJ et al (2012) Chlamydophila psittaci eradication with doxycycline as first-line targeted therapy for ocular adnexae lymphoma: final results of an international phase II trial. J Clin Oncol 30:2988–2994CrossRefPubMed

Fox JG, Wang TC (2007) Inflammation, atrophy, and gastric cancer. J Clin Investig 117:60–69CrossRefPubMed

Fox JG et al (2004) Gastroenteritis in NF-κB-deficient mice is produced with wild-type Camplyobacter jejuni but not with C. jejuni lacking cytolethal distending toxin despite persistent colonization with both strains. Infect Immun 72:1116–1125CrossRefPubMedPubMedCentral

Frankel AE, Coughlin LA, Kim J, Froehlich TW, Xie Y, Frenkel EP, Koh AY (2017) Metagenomic shotgun sequencing and unbiased metabolomic profiling identify specific human gut microbiota and metabolites associated with immune checkpoint therapy efficacy in melanoma patients. Neoplasia 19:848–855CrossRefPubMedPubMedCentral

Fukata M et al (2007) Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology 133:1869–1869.e1814CrossRefPubMed

Fukata M et al (2010) Constitutive activation of epithelial TLR4 augments inflammatory responses to mucosal injury and drives colitis-associated tumorigenesis. Inflamm Bowel Dis 17:1464–1473CrossRefPubMed

Gagnière J et al (2016) Gut microbiota imbalance and colorectal cancer. World J Gastroenterol 22:501CrossRefPubMedPubMedCentral

Gamallat Y et al (2016) Lactobacillus rhamnosus induced epithelial cell apoptosis, ameliorates inflammation and prevents colon cancer development in an animal model. Biomed Pharmacother 83:536–541CrossRefPubMed

Garaude J, Kent A, van Rooijen N, Blander JM (2012) Simultaneous targeting of toll-and nod-like receptors induces effective tumor-specific immune responses. Sci Transl Med 4:120ra116CrossRef

Garrett WS (2015) Cancer the microbiota. Science 348:80–86CrossRefPubMedPubMedCentral

Garrett WS et al (2010) Enterobacteriaceae act in concert with the gut microbiota to induce spontaneous and maternally transmitted colitis. Cell Host Microbe 8:292–300CrossRefPubMedPubMedCentral

Gill SR et al (2006) Metagenomic analysis of the human distal gut microbiome. Science 312:1355–1359CrossRefPubMedPubMedCentral

Gopalakrishnan V et al (2018) Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359:97–103CrossRefPubMed

Goubet A-G, Daillère R, Routy B, Derosa L, Roberti PM, Zitvogel L (2018) The impact of the intestinal microbiota in therapeutic responses against cancer. Comptes rendus biologies 341(5):284–289CrossRefPubMed

Grivennikov SI et al (2012) Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature 491:254CrossRefPubMedPubMedCentral

Grootaert C et al (2011) Bacterial monocultures, propionate, butyrate and H₂O₂ modulate the expression, secretion and structure of the fasting-induced adipose factor in gut epithelial cell lines. Environ microbiol 13:1778–1789CrossRefPubMed

Ha Y-H, Park D-G (2010) Effects of DCA on cell cycle proteins in colonocytes. J Korean Soc Coloproctol 26:254–259CrossRefPubMedPubMedCentral

Haiser HJ, Turnbaugh PJ (2012) Is it time for a metagenomic basis of therapeutics? Science 336:1253–1255CrossRefPubMed

Haiser HJ, Turnbaugh PJ (2013) Developing a metagenomic view of xenobiotic metabolism. Pharmacol Res 69:21–31CrossRefPubMed

Hajishengallis G, Darveau RP, Curtis MA (2012) The keystone-pathogen hypothesis. Nat Rev Microbiol 10:717CrossRefPubMedPubMedCentral

Han YW et al (2005) Identification and characterization of a novel adhesin unique to oral fusobacteria. J Bacteriol 187:5330–5340CrossRefPubMedPubMedCentral

Hold GL, Smith M, Grange C, Watt ER, El-Omar EM, Mukhopadhya I (2014) Role of the gut microbiota in inflammatory bowel disease pathogenesis: what have we learnt in the past 10 years? World J Gastroenterol WJG 20:1192CrossRefPubMed

Holmes E, Li JV, Marchesi JR, Nicholson JK (2012) Gut microbiota composition and activity in relation to host metabolic phenotype and disease risk. Cell Metab 16:559–564CrossRefPubMed

Hooper SJ, Crean S-J, Fardy MJ, Lewis MA, Spratt DA, Wade WG, Wilson MJ (2007) A molecular analysis of the bacteria present within oral squamous cell carcinoma. J Med Microbiol 56:1651–1659CrossRefPubMed

Hou J, Zheng H, Li P, Liu H, Zhou H, Yang X (2018) Distinct shifts in the oral microbiota are associated with the progression and aggravation of mucositis during radiotherapy. Radiother Oncol 129(1):44–51CrossRefPubMed

Hu S, Dong TS, Dalal SR, Wu F, Bissonnette M, Kwon JH, Chang EB (2011) The microbe-derived short chain fatty acid butyrate targets miRNA-dependent p21 gene expression in human colon cancer. PLoS One 6:e16221CrossRefPubMedPubMedCentral

Hu B et al (2013) Microbiota-induced activation of epithelial IL-6 signaling links inflammasome-driven inflammation with transmissible cancer. Proc Natl Acad Sci 110:9862–9867CrossRefPubMedPubMedCentral

Hu B et al (2016) The DNA-sensing AIM2 inflammasome controls radiation-induced cell death tissue injury. Science 354:765–768CrossRefPubMedPubMedCentral

Huttenhower C et al (2012) Structure, function and diversity of the healthy human microbiome. Nature 486:207CrossRef

Huycke MM, Gaskins HR (2004) Commensal bacteria, redox stress, and colorectal cancer: mechanisms and models. Exp Biol Med 229:586–597CrossRef

Iida N et al (2013) Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 342:967–970CrossRefPubMedPubMedCentral

Islami F, Kamangar F (2008) Helicobacter pylori and esophageal cancer risk: a meta-analysis. Cancer Prev Res 1:329–338CrossRef

Jones RM et al (2015) Lactobacilli modulate epithelial cytoprotection through the Nrf2 pathway. Cell Rep 12:1217–1225CrossRefPubMedPubMedCentral

Khor B, Gardet A, Xavier RJ (2011) Genetics and pathogenesis of inflammatory bowel disease. Nature 474:307CrossRefPubMedPubMedCentral

Klimesova K et al (2013) Altered gut microbiota promotes colitis-associated cancer in IL-1 receptor-associated kinase M deficient mice. Inflamm Bowel Dis 19:1266CrossRefPubMed

Kobayashi KS, Chamaillard M, Ogura Y, Henegariu O, Inohara N, Nunez G, Flavell RA (2005) Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 307:731–734CrossRefPubMed

Kostic AD et al (2012) Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res 22:292–298CrossRefPubMedPubMedCentral

Kostic AD et al (2013) Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe 14:207–215CrossRefPubMedPubMedCentral

Kroemer G, Galluzzi L, Kepp O, Zitvogel L (2013) Immunogenic cell death in cancer therapy. Annu Rev Immunol 31:51–72CrossRefPubMed

Le Chatelier E et al (2013) Richness of human gut microbiome correlates with metabolic markers. Nature 500:541CrossRefPubMed

Lecuit M et al (2004) Immunoproliferative small intestinal disease associated with Campylobacter jejuni New England. J Med 350:239–248

Lehouritis P et al (2015) Local bacteria affect the efficacy of chemotherapeutic drugs. Sci Rep 5:14554CrossRefPubMedPubMedCentral

Lofgren JL et al (2011) Lack of commensal flora in Helicobacter pylori-infected INS-GAS mice reduces gastritis and delays intraepithelial neoplasia. Gastroenterology 140:210–220.e214CrossRefPubMed

Louis P, Hold GL, Flint HJ (2014a) The gut microbiota, bacterial metabolites and colorectal cancer. Nat Rev Microbiol 12:661–672CrossRefPubMed

Louis P, Hold GL, Flint HJ (2014b) The gut microbiota, bacterial metabolites and colorectal cancer. Nat Rev Microbiol 12:661CrossRefPubMed

Lupp C, Robertson ML, Wickham ME, Sekirov I, Champion OL, Gaynor EC, Finlay BB (2007) Host-mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of Enterobacteriaceae. Cell Host Microbe 2:119–129CrossRefPubMed

Mabrok HB, Klopfleisch R, Ghanem KZ, Clavel T, Blaut M, Loh G (2011) Lignan transformation by gut bacteria lowers tumor burden in a gnotobiotic rat model of breast cancer. Carcinogenesis 33:203–208CrossRefPubMed

Matson V et al (2018) The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science 359:104–108CrossRefPubMedPubMedCentral

Mavragani IV, Laskaratou DA, Frey B, Candéias SM, Gaipl US, Lumniczky K, Georgakilas AG (2016) Key mechanisms involved in ionizing radiation-induced systemic effects. A current review. Toxicol Res 5:12–33CrossRef

McGovern DP et al (2005) Association between a complex insertion/deletion polymorphism in NOD1 (CARD4) and susceptibility to inflammatory bowel disease. Hum Mol Genet 14:1245–1250CrossRefPubMed

Mima K et al (2015) Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. Gut 341(5):284–289

Minemura M, Shimizu Y (2015) Gut microbiota and liver diseases. World J Gastroenterol WJG 21:1691CrossRefPubMed

Mitchell EP (2006) Gastrointestinal toxicity of chemotherapeutic agents. Semin Oncol 33(1):106–120CrossRefPubMed

Mittal D, Saccheri F, Vénéreau E, Pusterla T, Bianchi ME, Rescigno M (2010) TLR4-mediated skin carcinogenesis is dependent on immune and radioresistant cells. EMBO J 29:2242–2252CrossRefPubMedPubMedCentral

Moresco EMY, LaVine D, Beutler B (2011) Toll-like receptors. Curr Biol 21:R488–R493CrossRefPubMed

Morgan XC et al (2012) Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol 13:R79CrossRefPubMedPubMedCentral

Nath G, Singh H, Shukla V (1997) Chronic typhoid carriage and carcinoma of the gallbladder. Eur J Cancer Prev 6:557–559CrossRefPubMed

Nešić D, Hsu Y, Stebbins CE (2004) Assembly and function of a bacterial genotoxin. Nature 429:429CrossRefPubMed

Neufert C et al (2013) Tumor fibroblast-derived epiregulin promotes growth of colitis-associated neoplasms through ERK. J Clin Investig 123:1428–1443CrossRefPubMedPubMedCentral

Nougayrède J-P et al (2006) Escherichia coli induces DNA double-strand breaks in eukaryotic cells. Science 313:848–851CrossRefPubMed

Nyangale EP, Mottram DS, Gibson GR (2012) Gut microbial activity, implications for health and disease: the potential role of metabolite analysis. J Proteome Res 11:5573–5585CrossRefPubMed

Ochi A et al (2012) MyD88 inhibition amplifies dendritic cell capacity to promote pancreatic carcinogenesis via Th2 cells. J Exp Med 209:1671–1687CrossRefPubMedPubMedCentral

Ohnishi N et al (2008) Transgenic expression of Helicobacter pylori CagA induces gastrointestinal and hematopoietic neoplasms in mouse. Proc Natl Acad Sci 105:1003–1008CrossRefPubMedPubMedCentral

Pateras IS et al (2015) The DNA damage response and immune signaling alliance: is it good or bad? Nature decides when where. Pharmacol Ther 154:36–56CrossRefPubMed

Patwa LG, Fan TJ, Tchaptchet S, Liu Y, Lussier YA, Sartor RB, Hansen JJ (2011) Chronic intestinal inflammation induces stress-response genes in commensal. Escherichia coli. Gastroenterology 141:1842–1851.e1810CrossRefPubMed

Perez-Chanona E, Trinchieri G (2016) The role of microbiota in cancer therapy. Curr Opin Immunol 39:75–81CrossRefPubMedPubMedCentral

Petnicki-Ocwieja T, Hrncir T, Liu Y-J, Biswas A, Hudcovic T, Tlaskalova-Hogenova H, Kobayashi KS (2009) Nod2 is required for the regulation of commensal microbiota in the intestine. Proc Natl Acad Sci 106:15813–15818CrossRefPubMedPubMedCentral

Philipp B (2011) Bacterial degradation of bile salts. Appl Microbiol Biotechnol 89:903–915CrossRefPubMed

Plottel CS, Blaser MJ (2011) Microbiome malignancy. Cell Host Microbe 10:324–335CrossRefPubMedPubMedCentral

Pradere J-P, Dapito DH, Schwabe RF (2014) The Yin and Yang of toll-like receptors in cancer. Oncogene 33:3485–3495CrossRefPubMed

Putze J et al (2009) Genetic structure and distribution of the colibactin genomic island among members of the family Enterobacteriaceae. Infect Immun 77:4696–4703CrossRefPubMedPubMedCentral

Quante M et al (2012) Bile acid and inflammation activate gastric cardia stem cells in a mouse model of Barrett-like metaplasia. Cancer Cell 21:36–51CrossRefPubMedPubMedCentral

Quigley EM (2013) Gut bacteria in health and disease. Gastroenterol Hepatol 9:560

Raza MH, Siraj S, Arshad A, Waheed U, Aldakheel F, Alduraywish S, Arshad M (2017) ROS-modulated therapeutic approaches in cancer treatment. J Cancer Res Clin Oncol 143:1789–1809CrossRefPubMed

Robert C et al (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma New England. J Med 364:2517–2526

Routy B et al (2017) The influence of gut-decontamination prophylactic antibiotics on acute graft-versus-host disease and survival following allogeneic hematopoietic stem cell transplantation. OncoImmunology 6:e1258506CrossRefPubMed

Routy B et al (2018) Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359:91–97CrossRefPubMed

Roy S, Trinchieri G (2017) Microbiota: a key orchestrator of cancer therapy. Nat Rev Cancer 17(5):271–285CrossRefPubMed

Rubinstein MR, Wang X, Liu W, Hao Y, Cai G, Han YW (2013) Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. Cell Host Microbe 14:195–206CrossRefPubMedPubMedCentral

Russell WR et al (2011) High-protein, reduced-carbohydrate weight-loss diets promote metabolite profiles likely to be detrimental to colonic health. Am J Clin Nutr 93:1062–1072CrossRefPubMed

Salcedo R et al (2010) MyD88-mediated signaling prevents development of adenocarcinomas of the colon: role of interleukin 18. J Exp Med 207(8):1625–1636CrossRefPubMedPubMedCentral

Samet A, Śledzińska A, Krawczyk B, Hellmann A, Nowicki S, Kur J, Nowicki B (2013) Leukemia and risk of recurrent Escherichia coli bacteremia: genotyping implicates E. coli translocation from the colon to the bloodstream. Eur J Clin Microbiol Infect Dis 32:1393–1400CrossRefPubMedPubMedCentral

Sanapareddy N et al (2012) Increased rectal microbial richness is associated with the presence of colorectal adenomas in humans. ISME J 6:1858CrossRefPubMedPubMedCentral

Sancho-Martínez SM, Prieto-García L, Prieto M, López-Novoa JM, López-Hernández FJ (2012) Subcellular targets of cisplatin cytotoxicity: an integrated view. Pharmacol Ther 136:35–55CrossRefPubMed

Sartor RB, Mazmanian SK (2012) Intestinal microbes in inflammatory bowel diseases. Am J Gastroenterol Suppl 1:15–21CrossRef

Schiavoni G et al (2010) Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis. Cancer Res (canres.2788.2010)

Schwabe RF, Jobin C (2013a) The microbiome and cancer. Nat Rev Cancer 13:800–812CrossRefPubMedPubMedCentral

Sears CL, Myers LL, Lazenby A, Van Tassell RL (1995) Enterotoxigenic Bacteroides fragilis. Clin Infect Dis 20:S142–S148CrossRefPubMed

Seitz HK, Stickel F (2007) Molecular mechanisms of alcohol-mediated carcinogenesis. Nat Rev Cancer 7:599CrossRefPubMed

Selwyn FP, Cui JY, Klaassen CD (2015) RNA-Seq quantification of hepatic drug processing genes in germ-free mice. Drug Metab Dispos 43:1572–1580CrossRefPubMedPubMedCentral

Senff NJ et al (2008) European organization for research and treatment of cancer and international society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood 112:1600–1609CrossRefPubMed

Shanmughapriya S, Senthilkumar G, Vinodhini K, Das B, Vasanthi N, Natarajaseenivasan K (2012) Viral and bacterial aetiologies of epithelial ovarian cancer. Eur J Clin Microbiol Infect Dis 31:2311–2317CrossRefPubMed

Sharma P, Allison JP (2015) The future of immune checkpoint therapy. Science 348:56–61CrossRefPubMed

Shen S, Wong CH (2016) Bugging inflammation: role of the gut microbiota. Clin Transl Immunol 5:e72CrossRef

Shen Z et al (2009) Cytolethal distending toxin promotes Helicobacter cinaedi-associated typhlocolitis in interleukin-10-deficient mice. Infect Immun 77:2508–2516CrossRefPubMedPubMedCentral

Sivan A et al (2015) Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 350(6264):1084–1089CrossRefPubMedPubMedCentral

Smith JL, Bayles DO (2006) The contribution of cytolethal distending toxin to bacterial pathogenesis. Crit Rev Microbiol 32:227–248CrossRefPubMed

Sobhani I et al (2011) Microbial dysbiosis in colorectal cancer (CRC) patients. PLoS One 6:e16393CrossRefPubMedPubMedCentral

Stecher B et al (2012) Gut inflammation can boost horizontal gene transfer between pathogenic and commensal Enterobacteriaceae. Proc Natl Acad Sci 109:1269–1274CrossRefPubMedPubMedCentral

Taieb F, Petit C, Nougayrède J-P, Oswald E (2016) The enterobacterial genotoxins: cytolethal distending toxin and colibactin. EcoSal Plus. https://doi.org/10.1128/ecosalplus.ESP-0008-2016 CrossRefPubMed

Takemura N, Uematsu S (2017) Blockade of Tlr3 protects mice from lethal radiation-induced gastrointestinal syndrome: Tu-p6-9. Cytokine 100:152

Takemura N et al (2014) Blockade of TLR3 protects mice from lethal radiation-induced gastrointestinal syndrome. Nat Commun 5:3492CrossRefPubMed

Touchefeu Y et al (2014) Systematic review: the role of the gut microbiota in chemotherapy-or radiation-induced gastrointestinal mucositis—current evidence and potential clinical applications. Aliment Pharmacol Ther 40:409–421PubMed

Travaglione S, Fabbri A, Fiorentini C (2008) The Rho-activating CNF1 toxin from pathogenic E. coli: a risk factor for human cancer development? Infect Agents Cancer 3:4CrossRef

Tye H et al (2012) STAT3-driven upregulation of TLR2 promotes gastric tumorigenesis independent of tumor inflammation. Cancer Cell 22:466–478CrossRefPubMed

Vacchelli E et al (2013) Trial watch: anticancer radioimmunotherapy. Oncoimmunology 2:e25595CrossRefPubMedPubMedCentral

Van Duynhoven J et al (2011) Metabolic fate of polyphenols in the human superorganism. Proc Natl Acad Sci 108:4531–4538CrossRefPubMed

Vanhoecke BW, De Ryck TR, De Boel K, Wiles S, Boterberg T, Van de Wiele T, Swift S (2016) Low-dose irradiation affects the functional behavior of oral microbiota in the context of mucositis. Exp Biol Med 241:60–70CrossRef

Viaud S et al (2013) The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 342:971–976CrossRefPubMedPubMedCentral

Vijay-Kumar M et al (2010) Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science 328:228–231CrossRefPubMedPubMedCentral

Wallace BD et al (2010) Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science 330:831–835CrossRefPubMedPubMedCentral

Wang X, Huycke MM (2007) Extracellular superoxide production by Enterococcus faecalis promotes chromosomal instability in mammalian cells. Gastroenterology 132:551–561CrossRefPubMed

Wang Y, Kasper LH (2014) The role of microbiome in central nervous system disorders. Brain Behav Immun 38:1–12CrossRefPubMed

Wang T et al (2012a) Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers. ISME J 6:320CrossRefPubMed

Wang X, Yang Y, Moore DR, Nimmo SL, Lightfoot SA, Huycke MM (2012b) 4-Hydroxy-2-nonenal mediates genotoxicity and bystander effects caused by Enterococcus faecalis-infected macrophages. Gastroenterology 142:543–551.e547CrossRefPubMed

Wardill HR, Van Sebille YZ, Ciorba MA, Bowen JM (2018) Prophylactic probiotics for cancer therapy-induced diarrhoea: a meta-analysis. Curr Opin Support Palliat Care 12:187–197PubMed

Windey K, De Preter V, Verbeke K (2012) Relevance of protein fermentation to gut health. Mol Nutr Food Res 56:184–196CrossRefPubMed

Winter SE et al (2013) Host-derived nitrate boosts growth of E. coli in the inflamed gut. Science 339:708–711CrossRefPubMedPubMedCentral

Wu S et al (2009) A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med 15:1016CrossRefPubMedPubMedCentral

Yang Y (2015) Cancer immunotherapy: harnessing the immune system to battle cancer. J Clin Investig 125:3335–3337CrossRefPubMedPubMedCentral

Yoshimoto S et al (2013a) Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 499:97CrossRefPubMed

Yoshimoto S et al (2013b) Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 499:97–101CrossRefPubMed

Yu LX et al (2010) Endotoxin accumulation prevents carcinogen-induced apoptosis and promotes liver tumorigenesis in rodents. Hepatology 52:1322–1333CrossRefPubMed

Zhan Y et al (2013) Gut microbiota protects against gastrointestinal tumorigenesis caused by epithelial injury. Cancer Res 73:7199–7210CrossRefPubMed

Zhang H-L et al (2012) Profound impact of gut homeostasis on chemically-induced pro-tumorigenic inflammation and hepatocarcinogenesis in rats. J Hepatol 57:803–812CrossRefPubMed

Zitvogel L, Galluzzi L, Viaud S, Vétizou M, Daillère R, Merad M, Kroemer G (2015) Cancer and the gut microbiota: an unexpected link. Sci Transl Med 7:271ps271CrossRef

Title: Microbiota in cancer development and treatment
Authors: Muhammad Hassan Raza
Kamni Gul
Abida Arshad
Naveeda Riaz
Usman Waheed
Abdul Rauf
Fahad Aldakheel
Shatha Alduraywish
Maqbool Ur Rehman
Muhammad Abdullah
Muhammad Arshad
Publication date: 01-01-2019
Publisher: Springer Berlin Heidelberg
Published in: Journal of Cancer Research and Clinical Oncology / Issue 1/2019
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-018-2816-0

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2019

Multiple functions of HuR in urinary tumors

FGF8 induces therapy resistance in neoadjuvantly radiated rectal cancer

A novel prognostic signature of seven genes for the prediction in patients with thymoma

G-protein-coupled estrogen receptor suppresses the migration of osteosarcoma cells via post-translational regulation of Snail

Combination of gold nanoparticles with low-LET irradiation: an approach to enhance DNA DSB induction in HT29 colorectal cancer stem-like cells

DA-EPOCH-R improves the outcome over that of R-CHOP regimen for DLBCL patients below 60 years, GCB phenotype, and those with high-risk IPI, but not for double expressor lymphoma

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage